January 7, 2025 - 23:04

HOUSTON, January 07, 2025—Corebridge Financial, Inc. has announced the appointment of Polly Klane as the new General Counsel, effective February. In her role, Klane will report directly to Chief Executive Officer Kevin Hogan and will be responsible for overseeing the company’s legal, compliance, regulatory, corporate secretary, and government affairs functions.
Klane's extensive experience in the legal sector positions her well to contribute to Corebridge's strategic objectives. She will also join the Executive Leadership Team, where her insights will help shape the company's direction and governance. This transition follows the retirement of Christine Nixon, who held the General Counsel position and announced her departure last year after a distinguished career with the company.
Klane’s appointment signals Corebridge's commitment to strengthening its legal framework and enhancing its compliance measures as it navigates the complexities of the financial landscape. The company looks forward to her leadership and expertise in fostering a robust legal environment.
May 14, 2026 - 00:55
Aeluma Announces Third Quarter Fiscal 2026 Financial ResultsAeluma, Inc., a company specializing in compound semiconductor technologies, has released its financial results for the third quarter of fiscal year 2026. The report comes alongside several major...
May 13, 2026 - 11:31
MCK Q1 Deep Dive: Revenue Misses Analyst Expectations as Margin Initiatives ContinueHealthcare distributor McKesson reported first-quarter earnings that missed revenue expectations, though the company continued to push ahead with margin-focused initiatives. For the quarter ending...
May 12, 2026 - 23:07
Prudential Financial Declares Quarterly Dividend on Common StockNEWARK, N.J., May 12, 2026 -- Prudential Financial, Inc. has declared a quarterly dividend of $1.40 per share on its common stock. The payment is scheduled for June 11, 2026, and will go to...
May 12, 2026 - 03:06
Cellectis Reports First Quarter 2026 Financial ResultsCellectis has announced its financial results for the first quarter of 2026, alongside updates on its clinical pipeline and preclinical research programs. The company is advancing its pivotal...